EP2967121A1 - Nicotine and anatabine containing products and methods of making - Google Patents

Nicotine and anatabine containing products and methods of making

Info

Publication number
EP2967121A1
EP2967121A1 EP14715188.0A EP14715188A EP2967121A1 EP 2967121 A1 EP2967121 A1 EP 2967121A1 EP 14715188 A EP14715188 A EP 14715188A EP 2967121 A1 EP2967121 A1 EP 2967121A1
Authority
EP
European Patent Office
Prior art keywords
nicotine
anatabine
product
tobacco
containing product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14715188.0A
Other languages
German (de)
French (fr)
Inventor
Client Services Llc Altria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altria Client Services LLC
Original Assignee
Altria Client Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altria Client Services LLC filed Critical Altria Client Services LLC
Publication of EP2967121A1 publication Critical patent/EP2967121A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/38—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/38—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only nitrogen as hetero atom
    • A24B15/385—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only nitrogen as hetero atom in a five-membered ring

Definitions

  • This disclosure generally relates to nicotine-containing products.
  • Tobacco is a complex mixture of compounds with many different sensorial attributes. Many compounds in tobacco and tobacco smoke play a role in the sensorial aspects of tobacco products.
  • the present disclosure describes nicotine-containing products that also contain anatabine and methods of making such products.
  • a nicotine-containing product comprising anatabine.
  • the ratio of anatabine to nicotine is greater than 5:95. In some embodiments, the ratio of anatabine to nicotine is greater than 10:90. In some embodiments, the ratio of anatabine to nicotine is greater than 15:85.
  • the nicotine is synthetic nicotine. In some embodiments, the nicotine is tobacco-derived nicotine. In some embodiments, the anatabine is synthetic anatabine. In some embodiments, the anatabine is tobacco-derived anatabine.
  • Representative nicotine-containing products include, without limitation, a smokeable product and a smokeless product.
  • Representative smokeable products include, without limitation, a combustible product and a non-combustible product.
  • combustible products include a cigarette and a cigar.
  • Representative non-combustible products include, without limitation, an e-cigarette, an electronic smoking article, an aerosolized vapor products, and a heated tobacco product.
  • Representative smokeless products include snus, a pouch, a tab, a film, a stick, a woven product, a meltblown product, or a sintered piece.
  • such a product further includes an additive, a sweetener, a flavorant, a polymer, a fiber, filler, a plasticizer, or combinations thereof.
  • a method of making a nicotine-containing product typically includes providing a nicotine-containing product and introducing anatabine into a nicotine-containing product in an amount such that the anatabine to nicotine ratio is greater than 5:95. In some embodiments, the ratio of anatabine to nicotine is greater than 10:90. In some embodiments, the ratio of anatabine to nicotine is greater than 15:85.
  • the nicotine is synthetic nicotine. In some embodiments, the nicotine is tobacco-derived nicotine. In some embodiments, the anatabine is synthetic anatabine. In some embodiments, the anatabine is tobacco-derived anatabine.
  • Figure 1 shows the pathway by which nicotine and anatabine are produced.
  • Anatabine [2R,(+)]-l,2,3,6-Tetrahydro-2,3'-bipyridine
  • Anatabine has been shown to have affinity for nicotine acetylcholine receptors (Maciuk et al., 2008, J. Pharm. Biomed. Anal., 48:238-46) and has been shown to inhibit monoamine oxidase (US Patent No. 6,569,470) and the enzyme responsible for nicotine metabolism (Denton et al., 2004, Biochem. Pharmacol., 67:751-6).
  • anatabine may accentuate the nicotine response by binding to the nicotine receptor; anatabine may prolong the increased levels of neurotransmitters in the brain by inhibiting monoamine oxidase; and/or anatabine may extend the time between product use by inhibiting the enzyme responsible for nicotine metabolism.
  • the level of anatabine in dark tobacco is typically less than about 5% of the level of nicotine, but can be as high as 7% in burley tobacco.
  • Ratios of anatabine to nicotine can be greater than that found in cured tobacco leaf; for example, the ratio of anatabine to nicotine can be greater than about 5:95 (e.g., greater than about 6:94, 7:93, 8:92, 9:91, 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, or 50:50 anatabine-to-nicotine).
  • Nicotine-containing products that include anatabine can take any number of forms, and can include, for example, smokeable products (e.g., combustible smokeable products, non-combustible vapor-generating products (e.g., electronic e-cigarettes), smokeless products, and liquid aerosol formulations for use in, e.g., an electronic smoking article.
  • Smokeless products also can take many forms including, without limitation, dissolvable or disintegratable products (e.g., tabs, films, sticks), loose and pre-formed moist snuff (e.g., woven products, pouches, snus), and mouth-stable polymer products (e.g., meltblown products and sintered pieces).
  • the nicotine in a nicotine-containing product that also includes anatabine can be tobacco-derived nicotine, synthetic nicotine, or a combination thereof.
  • the anatabine in such a product can be tobacco-derived anatabine, synthetic anatabine, or a combination thereof.
  • Tobacco-derived nicotine and/or tobacco-derived anatabine generally include one or more tobacco organoleptic components in addition to the nicotine and/or anatabine.
  • Tobacco-derived nicotine and/or tobacco-derived anatabine can be extracted from raw tobacco (e.g., green leaf) or processed tobacco.
  • Processed tobacco can include cured tobacco (e.g., dark air-cured, dark fire-cured, flue cured), fermented tobacco, conditioned tobacco and/or pasteurized tobacco (see, for example, U.S. Patent Nos. 4,528,993; 4,660,577; 4,848,373; and 5,372,149, and U.S. Publication Nos. 2004/0118422 and 2005/0178398).
  • cured tobacco e.g., dark air-cured, dark fire-cured, flue cured
  • fermented tobacco conditioned tobacco and/or pasteurized tobacco
  • conditioned tobacco and/or pasteurized tobacco see, for example, U.S. Patent Nos. 4,528,993; 4,660,577; 4,848,373; and 5,372,149, and U.S. Publication Nos. 2004/0118422 and 2005/0178398).
  • Tobacco-derived nicotine and/or tobacco-derived anatabine can be obtained by mixing tobacco (i.e., raw or processed) with water or another solvent (e.g., ethanol) and removing the insoluble tobacco material. Nicotine and/or anatabine can be concentrated or purified from a tobacco extract using routine methods. Representative methods of obtaining nicotine and other alkaloids from tobacco are described, for example, in U.S. Patent Nos. 2,162,738; 3,139,436; 3,396,735; 4,153,063; 4,448,208; 5,487,792; and 5,684,155. In addition, nicotine, anatabine, or a salt thereof, can be produced synthetically. See, for example, U.S. Patent Nos. 4,442,292; 4,452,984; 6,995,265; 7,112,678; and 8,207,346.
  • a nicotine-containing product that includes anatabine can be substantially free of tobacco plant tissue.
  • tobacco plant tissue refers to processed or non-processed cellulosic parts (e.g., leaves, stems) of a member of the genus Nicotiana, but does not include extracts of tobacco (e.g., tobacco-derived nicotine or tobacco-derived anatabine).
  • a nicotine-containing product that includes anatabine also can include one or more organoleptic components extracted from raw or processed tobacco, yet be substantially free of tobacco plant tissue.
  • a nicotine-containing product that includes anatabeine as described herein also can include one or more additives, sweeteners, and/or flavorants, as well as one or more polymers, fibers, fillers, plasticizers, and/or other processing aids to provide a favorable flavor profile and tactile experience.
  • additives sweeteners, and/or flavorants
  • polymers such as polyethylene glycol dimethacrylate, polypropylene glycol dimethacrylate, polysulfate, polysulfate, polysulfate, polyethylene glycol dime, polyethylene glycol dimethoxysulfate, terethoxys, terpolymer, polymers, fibers, fillers, plasticizers, and/or other processing aids to provide a favorable flavor profile and tactile experience.
  • polymers fibers, fillers, plasticizers, and/or other processing aids
  • flavorants can be used in a nicotine-containing product that contains anatabine.
  • the flavorants can be natural or artificial.
  • suitable flavorants include wintergreen, cherry and berry type flavorants, various liqueurs and liquors (such as Dramboui, bourbon, scotch, and whiskey) spearmint, peppermint, lavender, cinnamon, cardamon, apium graveolents, clove, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, vanilla, lemon oil, orange oil, Japanese mint, cassia, caraway, cognac, jasmin, chamomile, menthol, ylangylang, sage, fennel, ginger, anise, coriander, coffee, and liquorish.
  • flavorants can be encapsulated.
  • a nicotine-containing product that includes anatabine as described herein can include a polymer.
  • a polymer can be any of a number of different biocompatible and biostable polymers.
  • the polymer is a thermoplastic polymer or a thermoplastic elastomer.
  • Representative polymers include, without limitation, polyurethanes, silicon polymers, polyesters, polyacrylates, polyethylenes, polypropylenes, polyetheramides, polystyrenes (e.g., acrylonitrile butadiene styrene, high impact polystyrenes (HIPS)) polyvinyl alcohols, polyvinyl acetates, polyvinyl chlorides, polybutyl acetates, butyl rubbers (e.g., polyisobutylenes), SEBS, SBS, and mixtures and copolymers thereof.
  • the polymer is a food-grade or medical-grade polymer (e.g., medical-grade polyurethane).
  • a nicotine-containing product containing anatabine also can include fillers such as starch, dicalcium phosphate, lactose, sorbitol, mannitol, and microcrystalline cellulose, calcium carbonate, dicalcium phosphate, calcium sulfate, clays, silica, glass particles, sodium lauryl sulfate (SLS), glyceryl palmitostearate, sodium benzoate, sodium stearyl fumarate, talc, and stearates (e.g., Mg or K), and waxes (e.g., glycerol monostearate, propylene glycol monostearate, and acetylated monoglycerides), stabilizers (e.g., ascorbic acid and monosterol citrate, BHT, or BHA), disintegrating agents (e.g., starch, sodium starch glycolate, cross caramellose, cross linked PVP), pH stabilizers, or preservatives.
  • fillers such as starch
  • a nicotine-containing product that includes anatabine also can include one or more plasticizers.
  • Plasticizers can soften the product and thus increase its flexibility. Suitable plasticizers include propylene glycol, glycerin, vegetable oil, and medium chain triglycerides. In some embodiments, the plasticizer can include phthalates. Esters of polycarboxylic acids with linear or branched aliphatic alcohols of moderate chain length can also be used as plasticizers.
  • Methods of making the nicotine-containing products described herein are known in the art. Methods of making such products often utilize automated or semi-automated processes, which can include cutting, pressing, shaping, tableting, rolling, dipping, coating, heating, melting, drying, sintering, melt blowing, needling, pouching, and combinations thereof.
  • automated or semi-automated processes can include cutting, pressing, shaping, tableting, rolling, dipping, coating, heating, melting, drying, sintering, melt blowing, needling, pouching, and combinations thereof.
  • the particular product and the method by which it is made will determine when and in what form (e.g., tobacco-derived or synthetic) the anatabine is introduced.
  • the anatabine can be introduced prior to any processing; in other products and/or processes, the anatabine can be introduced during processing; while yet in other products and/or processes, the anatabine can be introduced after processing is complete but prior to packaging. Depending upon the source of the nicotine and at what point the nicotine is introduced, the anatabine can be introduced together with the nicotine or separately.
  • the nicotine-containing products described herein that include anatabine can be packaged in any type of conventional or non-conventional manner.
  • a plurality of nicotine-containing products that include anatabine can be packaged in a container having a lid.
  • a plurality of nicotine-containing products that include anatabine can be stacked and packaged in a paper, plastic, and/or aluminum foil tube.
  • the packaging can have a child-resistant lid.

Abstract

Provided herein are nicotine-containing products that also contain anatabine. Also provided are methods of making such products.

Description

NICOTINE AND ANATABINE CONTAINING PRODUCTS AND
METHODS OF MAKING
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of priority to U.S. Application No. 61/786,344 filed March 15, 2013. The prior application is incorporated herein by reference in its entirety.
TECHNICAL FIELD
This disclosure generally relates to nicotine-containing products.
BACKGROUND
Tobacco is a complex mixture of compounds with many different sensorial attributes. Many compounds in tobacco and tobacco smoke play a role in the sensorial aspects of tobacco products.
SUMMARY
The present disclosure describes nicotine-containing products that also contain anatabine and methods of making such products.
In one aspect, a nicotine-containing product comprising anatabine is provided. In such a product, the ratio of anatabine to nicotine is greater than 5:95. In some embodiments, the ratio of anatabine to nicotine is greater than 10:90. In some embodiments, the ratio of anatabine to nicotine is greater than 15:85.
In some embodiments, the nicotine is synthetic nicotine. In some embodiments, the nicotine is tobacco-derived nicotine. In some embodiments, the anatabine is synthetic anatabine. In some embodiments, the anatabine is tobacco-derived anatabine.
Representative nicotine-containing products include, without limitation, a smokeable product and a smokeless product. Representative smokeable products include, without limitation, a combustible product and a non-combustible product. Representative
combustible products include a cigarette and a cigar. Representative non-combustible products include, without limitation, an e-cigarette, an electronic smoking article, an aerosolized vapor products, and a heated tobacco product. Representative smokeless products include snus, a pouch, a tab, a film, a stick, a woven product, a meltblown product, or a sintered piece. In some embodiments, such a product further includes an additive, a sweetener, a flavorant, a polymer, a fiber, filler, a plasticizer, or combinations thereof.
In another aspect, a method of making a nicotine-containing product is provided. Such a method typically includes providing a nicotine-containing product and introducing anatabine into a nicotine-containing product in an amount such that the anatabine to nicotine ratio is greater than 5:95. In some embodiments, the ratio of anatabine to nicotine is greater than 10:90. In some embodiments, the ratio of anatabine to nicotine is greater than 15:85.
In some embodiments, the nicotine is synthetic nicotine. In some embodiments, the nicotine is tobacco-derived nicotine. In some embodiments, the anatabine is synthetic anatabine. In some embodiments, the anatabine is tobacco-derived anatabine.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods and compositions of matter belong. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the methods and compositions of matter, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
DESCRIPTION OF DRAWINGS
Figure 1 shows the pathway by which nicotine and anatabine are produced.
DETAILED DESCRIPTION
This disclosure describes nicotine-containing products that, in addition to nicotine, include anatabine. Anatabine ([2R,(+)]-l,2,3,6-Tetrahydro-2,3'-bipyridine) is a minor alkaloid found in tobacco. Anatabine has been shown to have affinity for nicotine acetylcholine receptors (Maciuk et al., 2008, J. Pharm. Biomed. Anal., 48:238-46) and has been shown to inhibit monoamine oxidase (US Patent No. 6,569,470) and the enzyme responsible for nicotine metabolism (Denton et al., 2004, Biochem. Pharmacol., 67:751-6). Although not bound by any particular theory, anatabine may accentuate the nicotine response by binding to the nicotine receptor; anatabine may prolong the increased levels of neurotransmitters in the brain by inhibiting monoamine oxidase; and/or anatabine may extend the time between product use by inhibiting the enzyme responsible for nicotine metabolism.
The level of anatabine in dark tobacco is typically less than about 5% of the level of nicotine, but can be as high as 7% in burley tobacco. Ratios of anatabine to nicotine can be greater than that found in cured tobacco leaf; for example, the ratio of anatabine to nicotine can be greater than about 5:95 (e.g., greater than about 6:94, 7:93, 8:92, 9:91, 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, or 50:50 anatabine-to-nicotine).
Nicotine-containing products that include anatabine can take any number of forms, and can include, for example, smokeable products (e.g., combustible smokeable products, non-combustible vapor-generating products (e.g., electronic e-cigarettes), smokeless products, and liquid aerosol formulations for use in, e.g., an electronic smoking article. Smokeless products also can take many forms including, without limitation, dissolvable or disintegratable products (e.g., tabs, films, sticks), loose and pre-formed moist snuff (e.g., woven products, pouches, snus), and mouth-stable polymer products (e.g., meltblown products and sintered pieces). See, for example, US 2005/0244521; US 2006/0191548; US 2010/0163062; US 2010/0275936; US 2012/0024301; and US 2012/0031416; and US Patent Nos. 7,819,124; 7,918,231; 7,913,699; 7,980,251; and 7,901,512.
The nicotine in a nicotine-containing product that also includes anatabine can be tobacco-derived nicotine, synthetic nicotine, or a combination thereof. Similarly, the anatabine in such a product can be tobacco-derived anatabine, synthetic anatabine, or a combination thereof. Tobacco-derived nicotine and/or tobacco-derived anatabine generally include one or more tobacco organoleptic components in addition to the nicotine and/or anatabine. Tobacco-derived nicotine and/or tobacco-derived anatabine can be extracted from raw tobacco (e.g., green leaf) or processed tobacco. Processed tobacco can include cured tobacco (e.g., dark air-cured, dark fire-cured, flue cured), fermented tobacco, conditioned tobacco and/or pasteurized tobacco (see, for example, U.S. Patent Nos. 4,528,993; 4,660,577; 4,848,373; and 5,372,149, and U.S. Publication Nos. 2004/0118422 and 2005/0178398).
Tobacco-derived nicotine and/or tobacco-derived anatabine can be obtained by mixing tobacco (i.e., raw or processed) with water or another solvent (e.g., ethanol) and removing the insoluble tobacco material. Nicotine and/or anatabine can be concentrated or purified from a tobacco extract using routine methods. Representative methods of obtaining nicotine and other alkaloids from tobacco are described, for example, in U.S. Patent Nos. 2,162,738; 3,139,436; 3,396,735; 4,153,063; 4,448,208; 5,487,792; and 5,684,155. In addition, nicotine, anatabine, or a salt thereof, can be produced synthetically. See, for example, U.S. Patent Nos. 4,442,292; 4,452,984; 6,995,265; 7,112,678; and 8,207,346.
In some embodiments, a nicotine-containing product that includes anatabine can be substantially free of tobacco plant tissue. As used herein, the term "tobacco plant tissue" refers to processed or non-processed cellulosic parts (e.g., leaves, stems) of a member of the genus Nicotiana, but does not include extracts of tobacco (e.g., tobacco-derived nicotine or tobacco-derived anatabine). For example, a nicotine-containing product that includes anatabine also can include one or more organoleptic components extracted from raw or processed tobacco, yet be substantially free of tobacco plant tissue.
It would be understood by those skilled in the art that, in addition to nicotine and anatabine, a nicotine-containing product that includes anatabeine as described herein also can include one or more additives, sweeteners, and/or flavorants, as well as one or more polymers, fibers, fillers, plasticizers, and/or other processing aids to provide a favorable flavor profile and tactile experience. The following should be considered representative only and is not intended to be a comprehensive or exhaustive discussion of the components that can be found such a product.
A variety of flavorants can be used in a nicotine-containing product that contains anatabine. The flavorants can be natural or artificial. For example, suitable flavorants include wintergreen, cherry and berry type flavorants, various liqueurs and liquors (such as Dramboui, bourbon, scotch, and whiskey) spearmint, peppermint, lavender, cinnamon, cardamon, apium graveolents, clove, cascarilla, nutmeg, sandalwood, bergamot, geranium, honey essence, rose oil, vanilla, lemon oil, orange oil, Japanese mint, cassia, caraway, cognac, jasmin, chamomile, menthol, ylangylang, sage, fennel, ginger, anise, coriander, coffee, and liquorish. In some embodiments, flavorants can be encapsulated.
A nicotine-containing product that includes anatabine as described herein can include a polymer. A polymer can be any of a number of different biocompatible and biostable polymers. In some embodiments, the polymer is a thermoplastic polymer or a thermoplastic elastomer. Representative polymers include, without limitation, polyurethanes, silicon polymers, polyesters, polyacrylates, polyethylenes, polypropylenes, polyetheramides, polystyrenes (e.g., acrylonitrile butadiene styrene, high impact polystyrenes (HIPS)) polyvinyl alcohols, polyvinyl acetates, polyvinyl chlorides, polybutyl acetates, butyl rubbers (e.g., polyisobutylenes), SEBS, SBS, and mixtures and copolymers thereof. In certain embodiments, the polymer is a food-grade or medical-grade polymer (e.g., medical-grade polyurethane).
A nicotine-containing product containing anatabine also can include fillers such as starch, dicalcium phosphate, lactose, sorbitol, mannitol, and microcrystalline cellulose, calcium carbonate, dicalcium phosphate, calcium sulfate, clays, silica, glass particles, sodium lauryl sulfate (SLS), glyceryl palmitostearate, sodium benzoate, sodium stearyl fumarate, talc, and stearates (e.g., Mg or K), and waxes (e.g., glycerol monostearate, propylene glycol monostearate, and acetylated monoglycerides), stabilizers (e.g., ascorbic acid and monosterol citrate, BHT, or BHA), disintegrating agents (e.g., starch, sodium starch glycolate, cross caramellose, cross linked PVP), pH stabilizers, or preservatives.
A nicotine-containing product that includes anatabine also can include one or more plasticizers. Plasticizers can soften the product and thus increase its flexibility. Suitable plasticizers include propylene glycol, glycerin, vegetable oil, and medium chain triglycerides. In some embodiments, the plasticizer can include phthalates. Esters of polycarboxylic acids with linear or branched aliphatic alcohols of moderate chain length can also be used as plasticizers.
Methods of making the nicotine-containing products described herein (e.g., combustible and smokeless nicotine-containing products) are known in the art. Methods of making such products often utilize automated or semi-automated processes, which can include cutting, pressing, shaping, tableting, rolling, dipping, coating, heating, melting, drying, sintering, melt blowing, needling, pouching, and combinations thereof. The particular product and the method by which it is made will determine when and in what form (e.g., tobacco-derived or synthetic) the anatabine is introduced. In some products and/or processes, the anatabine can be introduced prior to any processing; in other products and/or processes, the anatabine can be introduced during processing; while yet in other products and/or processes, the anatabine can be introduced after processing is complete but prior to packaging. Depending upon the source of the nicotine and at what point the nicotine is introduced, the anatabine can be introduced together with the nicotine or separately.
The nicotine-containing products described herein that include anatabine can be packaged in any type of conventional or non-conventional manner. For example, a plurality of nicotine-containing products that include anatabine can be packaged in a container having a lid. In other embodiments, a plurality of nicotine-containing products that include anatabine can be stacked and packaged in a paper, plastic, and/or aluminum foil tube. The packaging can have a child-resistant lid. In accordance with the present invention, there may be employed conventional molecular biology, microbiology, biochemical, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature.
It is to be understood that, while the methods and compositions of matter have been described herein in conjunction with a number of different aspects, the foregoing description of the various aspects is intended to illustrate and not limit the scope of the methods and compositions of matter. Other aspects, advantages, and modifications are within the scope of the following claims.
Disclosed are methods and compositions that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed methods and compositions. These and other materials are disclosed herein, and it is understood that combinations, subsets, interactions, groups, etc. of these methods and compositions are disclosed. That is, while specific reference to each various individual and collective combinations and permutations of these compositions and methods may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular composition of matter or a particular method is disclosed and discussed and a number of compositions or methods are discussed, each and every combination and permutation of the compositions and the methods are specifically contemplated unless specifically indicated to the contrary. Likewise, any subset or combination of these is also specifically contemplated and disclosed.

Claims

WHAT IS CLAIMED IS:
1. A nicotine-containing product comprising anatabine, wherein the ratio of anatabine to nicotine is greater than 5:95.
2. The nicotine-containing product of claim 1, wherein the ratio of anatabine to nicotine is greater than 10:90.
3. The nicotine-containing product of claim 1, wherein the ratio of anatabine to nicotine is greater than 15:85.
4. The nicotine-containing product of claim 1, wherein the nicotine is synthetic nicotine.
5. The nicotine-containing product of claim 1, wherein the nicotine is tobacco- derived nicotine.
6. The nicotine-containing product of claim 1, wherein the anatabine is synthetic anatabine.
7. The nicotine-containing product of claim 1, wherein the anatabine is tobacco- derived anatabine.
8. The nicotine-containing product of claim 1, wherein the nicotine-containing product is selected from the group consisting of a smokeable product and a smokeless product.
9. The nicotine-containing product of claim 8, wherein the smokeable product is selected from the group consisting of a combustible product and a non-combustible product.
10. The nicotine-containing product of claim 9, wherein the combustible product is selected from the group consisting of a cigarette and a cigar.
11. The nicotine-containing product of claim 9, wherein the non-combustible product is selected from the group consisting of a cigarette, a heated tobacco product, an aerosolized vapor product, and an electronic smoking article.
12. The nicotine-containing product of claim 8, wherein the smokeless product is selected from the group consisting of snus, a pouch, a tabs, a film, a stick, a woven product, a meltblown product, and a sintered piece.
13. The nicotine-containing product of claim 1, further comprising an additive, a sweetener, a flavorant, a polymer, a fiber, filler, a plasticizer, or combinations thereof.
14. A method of making a nicotine-containing product, comprising:
providing a nicotine-containing product; and
introducing anatabine into a nicotine-containing product in an amount such that the anatabine to nicotine ratio is greater than 5:95.
15. The method of claim 14, wherein the ratio of anatabine to nicotine is greater than 10:90
The method of claim 14, wherein the ratio of anatabine to nicotine is greater than 15:85
17. The method of claim 14, wherein the nicotine is synthetic nicotine.
18. The method of claim 14, wherein the nicotine is tobacco-derived nicotine.
19. The method of claim 14, wherein the anatabine is synthetic anatabine. The method of claim 14, wherein the anatabine is tobacco-derived anatabine.
EP14715188.0A 2013-03-15 2014-03-12 Nicotine and anatabine containing products and methods of making Withdrawn EP2967121A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786344P 2013-03-15 2013-03-15
PCT/US2014/024451 WO2014150881A1 (en) 2013-03-15 2014-03-12 Nicotine and anatabine containing products and methods of making

Publications (1)

Publication Number Publication Date
EP2967121A1 true EP2967121A1 (en) 2016-01-20

Family

ID=50434301

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14715188.0A Withdrawn EP2967121A1 (en) 2013-03-15 2014-03-12 Nicotine and anatabine containing products and methods of making

Country Status (4)

Country Link
US (1) US20140261479A1 (en)
EP (1) EP2967121A1 (en)
CA (1) CA2905942A1 (en)
WO (1) WO2014150881A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10980273B2 (en) 2013-11-12 2021-04-20 VMR Products, LLC Vaporizer, charger and methods of use
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
KR102256889B1 (en) 2013-12-23 2021-05-31 쥴 랩스, 인크. Vaporization device systems and methods
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
KR102627987B1 (en) 2014-12-05 2024-01-22 쥴 랩스, 인크. Calibrated dose control
DE202017007467U1 (en) 2016-02-11 2021-12-08 Juul Labs, Inc. Fillable vaporizer cartridge
EP3419443A4 (en) 2016-02-11 2019-11-20 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
US10709165B2 (en) * 2016-09-27 2020-07-14 Bond Street Manufacturing Llc Vaporizable tobacco wax compositions
RU2754412C2 (en) 2017-04-24 2021-09-02 Свидиш Мэтч Норт Юроп Аб Flavored wet oral packaged nicotine product containing triglyceride
NO343402B1 (en) * 2017-04-24 2019-02-25 Swedish Match North Europe Ab A flavoured moist oral pouched nicotine product comprising triglyceride and a method for manufacturing thereof.
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
EP3723516A1 (en) 2017-12-15 2020-10-21 Swedish Match North Europe AB A flavoured moist oral pouched nicotine product comprising monoglyceride
US10897925B2 (en) * 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
EP3876760A1 (en) 2018-11-08 2021-09-15 Juul Labs, Inc. Cartridges for vaporizer devices
GB202006481D0 (en) * 2020-05-01 2020-06-17 Exhale Tech Ltd Composition and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2409413A1 (en) * 2000-05-16 2001-11-22 Blackbird Holdings, Inc. Systems and methods for conducting derivative trades electronically
US6534527B2 (en) * 2000-06-02 2003-03-18 Phytos, Inc. Edible herbal compositions for relieving nicotine craving
WO2004089126A1 (en) * 2003-04-01 2004-10-21 Shusei Takano Nicotine suction pipe and nicotine holder
US20110023762A1 (en) * 2009-07-31 2011-02-03 Willy Chen Structure for Sport Board
US20120325228A1 (en) * 2011-06-23 2012-12-27 Williams Jonnie R Alkaloid composition for e-cigarette
US20130012140A1 (en) * 2011-07-05 2013-01-10 Broadcom Corporation Wireless communication transceiver with reconfigurable poly spiral antenna
US20130048001A1 (en) * 2011-08-29 2013-02-28 Jonnie R. Williams Anatabine-Enriched Tobacco Products

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014150881A1 *

Also Published As

Publication number Publication date
WO2014150881A1 (en) 2014-09-25
CA2905942A1 (en) 2014-09-25
US20140261479A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US20140261479A1 (en) Nicotine-containing products and methods of making
US20230380475A1 (en) Smokeless tobacco article
US20230094995A1 (en) Oral tobacco product
US9986756B2 (en) Exhausted-tobacco oral product
CN109965339B (en) Tobacco treatment
EP2713780B1 (en) Methods for reducing the formation of tobacco specific nitrosamines in tobacco homogenates
GB2521738A (en) Tobacco material and treatment thereof
US20230210161A1 (en) Silicone smokeless tobacco product
US20230022076A1 (en) Tobacco composition
WO2014140346A1 (en) Methods for reducing one or more tobacco specific nitrosamines in tobacco material
GB2521739A (en) Tobacco material and treatment thereof
US20230372967A1 (en) Polymer encased smokeless tobacco products
AU2021277621B2 (en) Smoking article
CN102757865B (en) Carum carvi and dried ginger composite extract and purpose thereof as tobacco product additive
RU2772841C2 (en) Smoking product

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160518